| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 12/18/2007 | US7309778 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 12/18/2007 | US7309777 Antibodies against the PRO1556 polypeptide |
| 12/18/2007 | US7309774 for drug screening enzyme inhibitors for making fibrin deposits or blood clots more susceptible to removal by plasmin; fluorescence resonance energy transfer (FRET); genetic engineering |
| 12/18/2007 | US7309770 PRO1757 polypeptides |
| 12/18/2007 | US7309768 PRO4347 polypeptides |
| 12/18/2007 | US7309767 Used as pharmaceuticals, diagnostics, biosensors and bioreactors |
| 12/18/2007 | US7309765 PRO4349 polypeptides |
| 12/18/2007 | US7309764 PRO4401 polypeptide |
| 12/18/2007 | US7309763 Nucleotide sequences coding polypeptide for use in the treatment of cell proliferative and tumor disorders |
| 12/18/2007 | US7309762 PRO1360 polypeptides |
| 12/18/2007 | US7309760 Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions |
| 12/18/2007 | US7309759 Indolicidin peptide analogues containing at least two basic amino acids; bactericide |
| 12/18/2007 | US7309708 Serine protease inhibition via N-(distubstituted aminomethylcarbonyl)-2-[N-(1-sulfonylamido-1-cyclopropanyl)amido]pyrrolidines |
| 12/18/2007 | US7309694 Gene therapy; cytokine complex; anticancer agent |
| 12/18/2007 | US7309693 Comprises antagonistic mutein of MCP-1 (monocyte chemoattractant protein-1: macrophage chemotactic factor) |
| 12/18/2007 | US7309692 Inhibition of Grb2 and Crk1 gene products that interact with the bcr-abl product and participate in the transformation of Chronic myeloid leukemia |
| 12/18/2007 | US7309691 Combined pharmaceutical preparation containing LHRH-analogous substances and anti estrogens for treating gynaecological disorders |
| 12/18/2007 | US7309690 Parenterally or nasally administering zinc-free immune-system-inactive thymulin peptide analogue: Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asp; migraine, sciatica, neuropathy and inflammatory pain |
| 12/18/2007 | US7309689 Sustained peptide-release formulation |
| 12/18/2007 | US7309688 Topical application of formulation containing non-denatured, soy product in a carrier for inhibiting the progression of a cutaneous tumor |
| 12/18/2007 | US7309687 Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin |
| 12/18/2007 | US7309604 Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins |
| 12/18/2007 | US7309601 Ecteinascidia turbinata, biosynthesis of ecteinascidin compounds |
| 12/18/2007 | US7309586 Chimeric coiled coil molecules |
| 12/18/2007 | US7309585 Protein, therapy, diagnosis of cancer, to elicit an immune response |
| 12/18/2007 | US7309584 Mutations of the MDR1 P-glycoprotein that improves its ability to confer resistance to chemotherapeutic drugs |
| 12/18/2007 | US7309583 Nucleotide sequences coding polypeptide for use in the prevention of bacterial infection of mammals |
| 12/18/2007 | US7309578 Administering an antagonist inhibiting apoptosis of lung cells, diagnosing the disease |
| 12/18/2007 | US7309497 Injectable pharmaceutical composition for systematic administration of pharmacologically active ingredients |
| 12/18/2007 | US7309494 Contains connecting disulfide bridge; humanized monoclonal and polyclonal antibodies; diagnostic kits for respiratory syncytial virus |
| 12/18/2007 | US7309492 Soluble lymphotoxin-β receptors as therapeutic agents for the treatment of systemic lupus erythematosus |
| 12/18/2007 | US7309489 Monoclonal antibody that binds to mouse CD40L; inhibit CD40-L or anti-CD40 mAb induced B cell stimulation, IL-4-induced IgE stimulation and IL-4 induced CD23 induction in B cells |
| 12/18/2007 | US7309488 capable of efficient and selective adsorption of an antibody against beta 1-adrenoceptor and/or an antibody against M2 muscarinic receptor occurring in a body fluid (e.g. blood, plasma or the like) without requiring a pretreatment |
| 12/18/2007 | US7309485 Oligodendrocyte-myelin glycoprotein (OMgp)-specific binding agents, receptor binding assays; promoting nerve fiber growth |
| 12/18/2007 | US7309484 Compositions and methods for screening antibacterial compounds |
| 12/18/2007 | US7309483 Reducing pathological neovascularization in a human by administering to the human an agent capable of interfering with Ang2-mediated biological effects |
| 12/18/2007 | US7309482 Durability, efficiency, bind with high affinity to hair, skin, and nails |
| 12/18/2007 | CA2462459C Copolymers for suppression of autoimmune diseases, and methods of use |
| 12/18/2007 | CA2311754C A one dose syringe, comprising a freeze-dried protein composition, for administering of a volume less than 0.5 ml |
| 12/18/2007 | CA2299471C Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer |
| 12/18/2007 | CA2277377C Controlled release composition |
| 12/18/2007 | CA2249390C Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor |
| 12/18/2007 | CA2235400C Cartilage/bone inducing materials for reparation |
| 12/18/2007 | CA2233042C Specific binding members for human transforming growth factor beta; materials and methods |
| 12/18/2007 | CA2107476C Pharmaceutical packaging unit containing plasminogen activators for multiple bolus administration |
| 12/18/2007 | CA2062047C Fusion proteins for prodrug activation, the preparation and use thereof |
| 12/13/2007 | WO2007143694A2 Macrocyclic oximyl hepatitis c protease inhibitors |
| 12/13/2007 | WO2007143689A2 Compositions and methods for modulating vascular development |
| 12/13/2007 | WO2007143582A2 Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling |
| 12/13/2007 | WO2007143451A2 Targeted delivery of oncolytic viruses, anti-tumor proteins, plasmids, toxins, hemolysins & chemotherapy |
| 12/13/2007 | WO2007143411A2 Use of a botulinum toxin for treating a urethral stricture |
| 12/13/2007 | WO2007143410A2 Use of a botulinum toxin for treating a urethral stricture |
| 12/13/2007 | WO2007143294A1 Use of botulinum toxin for alleviating testicular pain |
| 12/13/2007 | WO2007143161A2 Use of proteins and peptides of the tgf-beta superfamily for purification and therapeutic methods |
| 12/13/2007 | WO2007143023A1 Soluble endoglin compounds and uses thereof for the treatment and prevention of cancer |
| 12/13/2007 | WO2007143006A2 Polymeric biosurfactants |
| 12/13/2007 | WO2007142986A2 Aminothiazole derivatives and their uses as antibacterial agents |
| 12/13/2007 | WO2007142711A2 Methods for diagnosing and treating cancer |
| 12/13/2007 | WO2007142667A2 Treatment of patients with autoantibody positive disease |
| 12/13/2007 | WO2007142628A1 Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof |
| 12/13/2007 | WO2007142542A2 Cationic milk proteins for treating mastitis |
| 12/13/2007 | WO2007142349A1 Hair growth composition |
| 12/13/2007 | WO2007142309A1 Method of screening drug for treating kidney glomerulus |
| 12/13/2007 | WO2007142304A1 SENSE OLIGONUCLEOTIDE CAPABLE OF CONTROLLING THE EXPRESSION OF iNOS AND COMPOSITION COMPRISING THE SAME |
| 12/13/2007 | WO2007142303A1 Method for controlling the amount of gene product, and agent for controlling the amount of gene product |
| 12/13/2007 | WO2007142288A1 Treatment of ischemic disease using erythropoietin |
| 12/13/2007 | WO2007142286A1 Fatigue-reducing agent |
| 12/13/2007 | WO2007142230A1 Lipid-metabolism-improving agent |
| 12/13/2007 | WO2007141971A1 Dna encoding polypeptide capable of modulating muscle-specific tyrosine kinase activity |
| 12/13/2007 | WO2007141667A2 Immunosuppressive extract of cordyceps sinensis and uses thereof |
| 12/13/2007 | WO2007141533A2 Fkbp-l and uses thereof |
| 12/13/2007 | WO2007141344A2 Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic |
| 12/13/2007 | WO2007141043A2 Monoclonal anti-annexin a3 antibodies for the detection of prostate carcinoma |
| 12/13/2007 | WO2007141005A1 Use of glutamyl aminopeptidase (enpep) as a therapeutic or diagnostic target |
| 12/13/2007 | WO2007141004A1 Use of adipsin (adn) as a therapeutic or diagnostic target |
| 12/13/2007 | WO2007140953A1 Peptide associated with rheumatic fever (parf) and its use as a diagnostic marker |
| 12/13/2007 | WO2007140906A1 Use of leucyl/cystinyl aminopeptidase (lnpep) as a therapeutic or diagnostic target |
| 12/13/2007 | WO2007140667A1 A ptd-vp3 fusion protein as anti-tumor medecine and preparing process |
| 12/13/2007 | WO2007140625A1 Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects |
| 12/13/2007 | WO2007140619A1 Derivatized insulin oligomers |
| 12/13/2007 | WO2007140618A1 Modified protein toxins targeting cytokine -receptor bearing cells and use thereof for treating disease |
| 12/13/2007 | WO2007140590A1 Methods and compositions for inducing bone synthesis |
| 12/13/2007 | WO2007140545A1 Methods of diagnosis and treatment of m. tuberculosis infection and reagents therefore |
| 12/13/2007 | WO2007140505A2 Vaccine carrier |
| 12/13/2007 | WO2007121546A8 Use of mas-g-protein-coupled receptor agonists in the treatment of the metabolic syndrome, its components and its complications |
| 12/13/2007 | WO2007121411A3 Glucagon-like peptide 1(glp-1) pharmaceutical formulations |
| 12/13/2007 | WO2007116428A8 Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis |
| 12/13/2007 | WO2007110811A3 Use of the staudinger ligation in in vivo assembly of a biologically active compound |
| 12/13/2007 | WO2007104736A3 Acylated single chain insulin |
| 12/13/2007 | WO2007103510A3 Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders |
| 12/13/2007 | WO2007102957A3 Skin care compositions including hexapeptide complexes and methods of their manufacture |
| 12/13/2007 | WO2007101602A3 Chimeric kunitz domains and their use |
| 12/13/2007 | WO2007098106A3 Respiratory tract delivery of interferon-tau |
| 12/13/2007 | WO2007084507A3 [ψ[CH2NH]PG4] GLYCOPEPTIDE ANTIBIOTIC ANALOGS |
| 12/13/2007 | WO2007070824A3 Use of eif-5a to kill multiple myeloma cells |
| 12/13/2007 | WO2007059211A3 Methods of treating fibrosing diseases by induction of immune tolerance |
| 12/13/2007 | WO2007048034A3 Use of androgens for the treatment of parkinson' s disease |
| 12/13/2007 | WO2007047194A3 Methods for treating mitf-related disorders |
| 12/13/2007 | WO2007041632A3 Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection |
| 12/13/2007 | WO2007037795A3 Stable aqueous protein or antibody pharmaceutical formulations and their preparation |